INBX (Inhibrx Biosciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by INBX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-04 | Jon Faiz Kayyem | Director | A | — | — |
| 2026-06-04 | KIMBERLY MANHARD | Director | A | — | — |
| 2026-06-04 | DOUGLAS FORSYTH | Director | A | — | — |
| 2026-06-04 | Kristiina MD Vuori | Director | A | — | — |
| 2026-04-27 | David Matly | President | A | — | — |
| 2025-10-09 | David C. Ott | 10%+ Owner | Sell | — | — |
| 2025-05-29 | Kristiina MD Vuori | Director | A | — | — |
| 2025-05-29 | KIMBERLY MANHARD | Director | A | — | — |
| 2025-05-29 | Jon Faiz Kayyem | Director | A | — | — |
| 2025-05-29 | DOUGLAS FORSYTH | Director | A | — | — |
| 2025-04-02 | David Matly | President | A | — | — |
| 2025-04-02 | Kelly Deck | Chief Financial Officer | A | — | — |
| 2025-03-28 | Jon Faiz Kayyem | Director | G | — | — |
| 2024-12-17 | Jon Faiz Kayyem | Director | G | — | — |
| 2024-12-06 | Jon Faiz Kayyem | Director | G | — | — |
| 2024-11-22 | Jon Faiz Kayyem | Director | Buy | — | — |
| 2024-10-07 | Kristiina MD Vuori | Director | Buy | — | — |
| 2024-09-16 | Mark Lappe | Chief Executive Officer | Buy | — | — |
| 2024-09-12 | Kristiina MD Vuori | Director | Buy | — | — |
| 2024-09-10 | Mark Lappe | Chief Executive Officer | Buy | — | — |
| 2024-09-03 | Kristiina MD Vuori | Director | Buy | — | — |
| 2024-09-03 | Mark Lappe | Chief Executive Officer | Buy | — | — |
| 2024-08-30 | KIMBERLY MANHARD | Director | Buy | — | — |
| 2024-08-26 | DOUGLAS FORSYTH | Director | Buy | — | — |
| 2024-08-22 | Mark Lappe | Chief Executive Officer | Buy | — | — |
| 2024-06-24 | Jon Faiz Kayyem | Director | G | — | — |
| 2024-06-07 | Jon Faiz Kayyem | Director | Buy | — | — |
| 2024-06-03 | Viking Global Opportunities GP LLC | 10%+ Owner | J | — | — |
| 2024-05-24 | Brendan P. Eckelman | Chief Scientific Officer | M | — | — |
| 2024-05-08 | Kelly Deck | Chief Financial Officer | M | — | — |
| 2024-03-28 | Kelly Deck | Chief Financial Officer | M | — | — |
| 2024-03-22 | Kelly Deck | Chief Financial Officer | M | — | — |
| 2024-03-15 | Brendan P. Eckelman | Chief Scientific Officer | M | — | — |
| 2024-03-15 | Kelly Deck | Chief Financial Officer | M | — | — |
| 2024-03-12 | Kelly Deck | Chief Financial Officer | M | — | — |
| 2024-03-12 | Brendan P. Eckelman | Chief Scientific Officer | M | — | — |
| 2024-03-06 | Kelly Deck | Chief Financial Officer | M | — | — |
| 2023-08-30 | Viking Global Opportunities GP LLC | 10%+ Owner | Buy | — | — |
| 2023-05-30 | DOUGLAS FORSYTH | Director | A | — | — |
| 2023-05-30 | Jon Faiz Kayyem | Director | A | — | — |
| 2023-05-30 | KIMBERLY MANHARD | Director | A | — | — |
| 2023-05-30 | Kristiina MD Vuori | Director | A | — | — |
| 2023-03-02 | Brendan P. Eckelman | Chief Scientific Officer | Sell | — | — |
| 2023-03-01 | Mark Lappe | Chief Executive Officer | Sell | — | — |
| 2023-02-02 | Brendan P. Eckelman | Chief Scientific Officer | Sell | — | — |
| 2023-01-24 | Mark Lappe | Chief Executive Officer | Sell | — | — |
| 2023-01-23 | Jon Faiz Kayyem | Director | Sell | — | — |
| 2023-01-04 | Eckelman Living Trust Dated February 5, 2014 | 10%+ Owner | Sell | — | — |
| 2023-01-03 | Mark Lappe | Chief Executive Officer | A | — | — |
| 2023-01-03 | Kelly Deck | Chief Financial Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,267,823 | — |
| — | Chief Executive Officer | 705,548 | — |
| — | Director | 419,360 | — |
| — | Director | 224,564 | — |
| — | Director | 20,443 | — |
| — | Director | 10,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INBX quote page; the site-wide leaderboard is on the insider transactions hub.